Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P20827
UPID:
EFNA1_HUMAN
Alternative names:
EPH-related receptor tyrosine kinase ligand 1; Immediate early response protein B61; Tumor necrosis factor alpha-induced protein 4
Alternative UPACC:
P20827; D3DV86; Q5SR60; Q5SR61; Q6I9T9; Q8N578
Background:
Ephrin-A1, known as EPH-related receptor tyrosine kinase ligand 1, plays a pivotal role in neuronal, vascular, and epithelial development through its interaction with Eph receptors. It facilitates crucial processes such as migration, repulsion, and adhesion by engaging in bidirectional signaling. Moreover, Ephrin-A1 is instrumental in angiogenesis and tumor neovascularization, influencing cell migration and assembly via RAC1 GTPase activation.
Therapeutic significance:
Understanding the role of Ephrin-A1 could open doors to potential therapeutic strategies. Its ability to activate and down-regulate EPHA2 presents anti-oncogenic effects in tumor cells, highlighting its significance in cancer research. Additionally, its negative regulatory role in glioma tumorigenesis underscores its potential as a therapeutic target.